Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST: Zolbetuximab + EOX in Advanced Gastric/GEJ/Esophageal Adenocarcinoma
NCT01630083Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2012
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Jul 2012; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01630083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630083.